News from spherix global insights A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
Latest
Oct 22, 2020, 13:00 ET Spherix Global Insights Climbs the Ranks on Two Lists Recognizing Greater Philadelphia's Fastest Growing Companies
In their second year of eligibility, Spherix Global Insights, a market intelligence firm focusing on immunology, nephrology, and neurology markets,...
Sep 30, 2020, 07:30 ET Rheumatologists and Nephrologists Anxiously Await New Potential Treatments for Systemic Lupus Erythematosus and Lupus Nephritis, According to Spherix Global Insights
Rheumatologists have long struggled to effectively treat patients with systemic lupus erythematosus (SLE) given the wide heterogeneity of the disease ...
Sep 24, 2020, 11:05 ET The Need for Greater Efficacy Drives Increased Switching from Branded TNF Inhibitors to Takeda's Entyvio, Janssen's Stelara, and Pfizer's Xeljanz in US Inflammatory Bowel Disease Market
The 2020 audit included in Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (US) service focuses on a critical facet of overall ...
Sep 16, 2020, 07:30 ET Following a Delayed Launch, Bristol Myers Squibb's Zeposia has Begun to Successfully Establish Itself as a Low-Burden Option Within the S1P Receptor Modulator Class, According to Spherix Global Insights
With expanded use of new oral disease-modifying therapies (DMTs) in the multiple sclerosis (MS) market, oral DMT class share has increased slightly...
Sep 15, 2020, 04:00 ET Despite Most Specialty Physician Practices Reopening, Engagement with the Pharmaceutical Industry Continues to be Largely Virtual, Placing Added Pressure on Manufacturers Attempting to Introduce New Therapies
In March, Spherix began tracking the impact of COVID-19 among specialty physicians, specifically dermatologists, gastroenterologists, nephrologists,...
Sep 09, 2020, 07:50 ET Recent, Positive Efficacy Data for Janssen's Stelara in Refractory Crohn's Disease Significantly Boost Patient Share for the IL-12/23 Inhibitor, According to Spherix Global Insights
According to the latest report published as part of Spherix's RealTime Dynamix™: Inflammatory Bowel Disease US service, gastroenterologists (n=100)...
Sep 08, 2020, 07:50 ET SGLT2 Inhibitors Could Induce a Seismic Shift in Treatment of Diabetic Kidney Disease in the US, According to Spherix Global Insights
With the increasing prevalence of diabetes across the United States, concern about diabetic kidney disease (DKD) remains high among nephrologists,...
Aug 31, 2020, 07:30 ET Nephrologists Point to Profound Unmet Need for New Agents to Treat Glomerular Diseases Such as IgA Nephropathy, Focal Segmental Glomerulosclerosis (FSGS), and Lupus Nephritis
Glomerular diseases pose some of the greatest challenges to nephrologists: they are progressive and potentially debilitating diseases, often have...
Aug 27, 2020, 13:01 ET Spherix Global Insights Releases 2021 Publication Plan and Announces New Service, Launch Dynamix™, Fueled by Growing Client Demand
Since its founding in 2015, Spherix Global Insights has been offering two key services to clients in the biopharma space, RealTime Dynamix™ and...
Aug 24, 2020, 15:46 ET The US Hyperkalemia Market Remains a Battle Ground Between AstraZeneca's LOKELMA (zirconium sodium cyclosilicate) and Vifor/Relypsa's VELTASSA (patiromer FOS)
Despite the recent emergence of new therapeutic options to treat hyperkalemia, namely Vifor/Relypsa's Veltassa (approved in 2016) and AstraZeneca's...
Aug 20, 2020, 05:00 ET Dermatologists Are Extremely Satisfied with Sanofi/Regeneron's Dupixent in Atopic Dermatitis, Though the Brand Leaves Certain Patient Segments Untapped: Will JAK Inhibitors Be the One to Fill the Gap?
Atopic dermatitis (AD), commonly referred to as eczema, affects millions of patients across the globe. In 2017, Sanofi/Regeneron's Dupixent, an...
Aug 18, 2020, 07:30 ET Recent Label Revisions Related to Constipation and Hypertension Generate Minimal Drag on the Decision to Prescribe Amgen/Novartis' Aimovig as a Preventive Treatment for Migraine
Distinctive prescribing patterns and drivers of brand selection among the subcutaneous (SC) calcitonin gene-related peptide (CGRP) monoclonal...
Aug 13, 2020, 13:04 ET Primary Care Providers Report High Prevalence of Chronic Kidney Disease and Categorize It as One of the Most Challenging Conditions to Manage
According to the National Kidney Foundation, one in three Americans over the age of 20 (a striking 73 million people) are at increased risk for...
Jul 30, 2020, 07:50 ET Takeda's Entyvio and Janssen's Stelara Share of Inflammatory Bowel Disease Biologic-Naive Patients Continues to Increase as This Patient Group Expands Their Involvement in the Decision-Making Process
The 2020 audit included in Spherix's RealWorld Dynamix™: Biologic/Small Molecule New Starts in IBD (US) service focuses on a key bellwether of the...
Jul 20, 2020, 04:30 ET Alternate Mechanism Biologics and Adalimumab Biosimilar Prescribing Increases at the Expense of AbbVie's Humira in the EU5 Inflammatory Bowel Disease Market, Despite the Significant Impact of COVID-19 on Gastroenterology Practitioners
According to the latest report published as part of Spherix's RealTime Dynamix™: Inflammatory Bowel Disease (EU) service, EU5 gastroenterologists...
Jul 14, 2020, 13:06 ET Treatment of Anemia Among Hematology/Oncology Specialists Spans Diverse Patient Types, Many of Which Have Multiple Contributory Factors
Spherix recently fielded a survey of 152 hematologists/oncologists in the US in order to assess the current and future treatment paradigms of anemia...
Jul 06, 2020, 12:22 ET COVID-19 Continues to Disrupt Patient Care Among Specialty Physicians, Though There Are Early Signs That Recovery is on the Horizon
Results from the seventh wave of an ongoing study examining the impact of COVID-19 on specialty physician practices were released last week and offer ...
Jul 02, 2020, 14:10 ET Massive Shift in Practice Patterns in Psoriatic Arthritis as Rheumatologists Lean Toward Increased Use of JAK inhibitors and Novel Biologics
Over the past four years, multiple new agents have been FDA approved for the treatment of psoriatic arthritis (PsA), including Pfizer's Xeljanz, Eli...
Jul 01, 2020, 04:30 ET While Gilead/Galapagos' Filgotinib Will Have to Contend with the Early Success of AbbVie's Rinvoq in the US Rheumatoid Arthritis Market, Eli Lilly's Olumiant is Likely to be the More Formidable Foe in the EU
Analysis of the most recent semiannual report included in Spherix's RealTime Dynamix™: Rheumatoid Arthritis (EU) service, which captured the...
Jun 30, 2020, 08:00 ET Eli Lilly's Reyvow Struggles to Gain Ground in the Acute Segment of the US Migraine Market, Overshadowed by AbbVie's Ubrelvy and Biohaven's Nurtec ODT, According to Spherix Global Insights
The number of companies active in the migraine space continues to expand, with Biohaven and Lundbeck providing the newest additions following their...
Jun 23, 2020, 04:30 ET EU5 Rheumatologists Expect the Introduction of Janssen's Tremfya in Psoriatic Arthritis to Blunt Anticipated Growth of Eli Lilly's Taltz, Novartis' Cosentyx, and Pfizer's Xeljanz
Spherix recently published the inaugural report of the semiannual report series included in their RealTime Dynamix™: Psoriatic Arthritis (EU)...
Jun 18, 2020, 16:20 ET Nephrologists Are Hesitant to Fully Embrace Janssen's INVOKANA Despite Being the First and Only SGLT2 Inhibitor with an FDA Indication to Treat Diabetic Kidney Disease
Millions of patients across the United States suffer from Type 2 diabetes, and one-quarter or more of those patients also have kidney disease, making ...
Jun 16, 2020, 13:17 ET Bristol Myers Squibb's Zeposia and Janssen's Ponesimod Could Be Early-Line Winners, While Biogen's Vumerity Appears Relegated to Tolerability Switches Within the Fumarate Class
Neurologist-reported treatment patterns in multiple sclerosis (MS) reveal a continued trend of using more high-efficacy disease-modifying therapies...
Jun 09, 2020, 13:40 ET Rapid Uptake of Skyrizi Protects the AbbVie Portfolio in Plaque Psoriasis as Humira Share Continues to Dwindle in the First-Line Setting
The 2020 audit included in Spherix's RealWorld Dynamix™: Biologic/Small Molecule New Starts in Plaque Psoriasis (US) service focuses on one of the...
Jun 04, 2020, 19:00 ET Less Than One Year Post Launch, AbbVie's Rinvoq Disrupts the Rheumatoid Arthritis Treatment Landscape, While a Rich Pipeline Waits in the Wings
The latest quarterly report included in Spherix's RealTime Dynamix: Rheumatoid Arthritis (US) service captures the responses of 105 rheumatologists...
